propranolol has been researched along with Local Neoplasm Recurrence in 27 studies
Propranolol: A widely used non-cardioselective beta-adrenergic antagonist. Propranolol has been used for MYOCARDIAL INFARCTION; ARRHYTHMIA; ANGINA PECTORIS; HYPERTENSION; HYPERTHYROIDISM; MIGRAINE; PHEOCHROMOCYTOMA; and ANXIETY but adverse effects instigate replacement by newer drugs.
propranolol : A propanolamine that is propan-2-ol substituted by a propan-2-ylamino group at position 1 and a naphthalen-1-yloxy group at position 3.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The goal of this neoadjuvant window of opportunity study is to prospectively evaluate the activity of propranolol monotherapy in patients with cutaneous angiosarcoma." | 9.34 | PropAngio study protocol: a neoadjuvant trial on the efficacy of propranolol monotherapy in cutaneous angiosarcoma-a proof of principle study. ( Beijnen, JH; Haas, RL; Heinhuis, KM; Huitema, ADR; IJzerman, NS; Koenen, AM; Steeghs, N; van der Graaf, WTA; van Houdt, WJ, 2020) |
| "Propranolol has emerged as a first line agent in the management of hemangiomas." | 8.31 | Bleomycin-triamcinolone sclerotherapy in the management of propranolol resistant infantile hemangioma of the maxillofacial region: A single arm prospective evaluation of clinical outcome and Doppler ultrasound parameters. ( Bera, RN; Pandey, V; Tiwari, P, 2023) |
| "Oral propranolol is the treatment of choice for infantile hemangiomas." | 8.02 | Recurrence rate of infantile hemangioma after oral propranolol therapy. ( Byeon, JO; Frongia, G; Günther, P; Mehrabi, A, 2021) |
| "The outcomes of propranolol treatment remain controversial for parotid hemangiomas, which may be inferior to outcomes for infantile hemangiomas (IHs) at other sites." | 8.02 | Oral propranolol therapy in parotid hemangiomas: A retrospective comparison with other infantile hemangiomas. ( Bi, J; Gao, Q; Huo, R; Li, S; Li, X; Lv, R; Wang, L; Xu, G, 2021) |
| "To study the clinical effect of oral propranolol in the treatment of respiratory hemangioma in infants and young children." | 7.96 | [Clinical effect of propranolol in the treatment of respiratory hemangioma in infants and young children]. ( Chen, YQ; Ding, XF; Zhong, LL, 2020) |
| "Oral propranolol (OP) demonstrated high efficacy and safety profile for treatment of critical infantile hemangiomas (IHs)." | 7.96 | A new clinical and dermoscopic monitoring of infantile hemangiomas treated with oral propranolol. ( Caini, M; Cartocci, A; Cevenini, G; Cinotti, E; de Quattro, M; Fiorani, D; Ierardi, F; Oranges, T; Pianigiani, E; Rubegni, P; Tognetti, L, 2020) |
| "Few specific reports have addressed propranolol as a treatment for parotid hemangioma, and its mechanism remains unclear." | 7.83 | Use of propranolol for parotid hemangioma. ( Chang, L; Chen, H; Jin, Y; Lin, X; Lv, D; Ma, G; Qiu, Y; Wang, T; Yang, X; Ying, H; Yu, W, 2016) |
| "Propranolol has been widely used in treating infantile hemangiomas (IHs)." | 7.80 | Propranolol enhanced adipogenesis instead of induction of apoptosis of hemangiomas stem cells. ( Chang, M; Ma, X; Ma, Y; Ouyang, T; Xin, S; Zhao, T, 2014) |
| "Although propranolol has become the first-line therapy for infantile haemangiomas (IHs), no study has yet investigated factors associated with the risk of relapse in children with IH treated with propranolol after cessation of treatment." | 7.79 | Factors associated with the relapse of infantile haemangiomas in children treated with oral propranolol. ( Ahogo, CK; Boralevi, F; Colona, V; Diallo, A; Ezzedine, K; Léauté-Labrèze, C; Prey, S; Taïeb, A, 2013) |
| "To report the efficacy of propranolol as first-line treatment of head and neck hemangiomas in children and to present an optimized protocol for treating hemangiomas." | 7.77 | Propranolol as first-line treatment of head and neck hemangiomas. ( Ayari-Khalfallah, S; Froehlich, P; Fuchsmann, C; Giguere, C; Guibaud, L; McCone, C; Powell, J; Quintal, MC, 2011) |
| "The successful management of subglottic hemangioma with propranolol has been reported." | 7.76 | Management of infantile subglottic hemangioma: acebutolol or propranolol? ( Amedro, P; Bigorre, M; Blanchet, C; Mondain, M; Nicollas, R, 2010) |
| "Propranolol was useful as first-line or single-agent treatment of facial infantile haemangioma in Chinese children, and gave rise to minimal side-effects." | 7.76 | Use of propranolol in infantile haemangioma among Chinese children. ( Chan, HB; Chik, KK; Luk, CK; Tan, HY, 2010) |
| "Infantile hemangiomas are the most common tumor of childhood and undergo rapid growth during early infancy followed by gradual involution." | 5.48 | Prolonged growth of infantile hemangioma after pulsed dye laser and oral propranolol treatment. ( Kagami, S; Kaneko, M; Katori, T; Kishi, A, 2018) |
| "The goal of this neoadjuvant window of opportunity study is to prospectively evaluate the activity of propranolol monotherapy in patients with cutaneous angiosarcoma." | 5.34 | PropAngio study protocol: a neoadjuvant trial on the efficacy of propranolol monotherapy in cutaneous angiosarcoma-a proof of principle study. ( Beijnen, JH; Haas, RL; Heinhuis, KM; Huitema, ADR; IJzerman, NS; Koenen, AM; Steeghs, N; van der Graaf, WTA; van Houdt, WJ, 2020) |
| "Propranolol has emerged as a first line agent in the management of hemangiomas." | 4.31 | Bleomycin-triamcinolone sclerotherapy in the management of propranolol resistant infantile hemangioma of the maxillofacial region: A single arm prospective evaluation of clinical outcome and Doppler ultrasound parameters. ( Bera, RN; Pandey, V; Tiwari, P, 2023) |
| "Oral propranolol is the treatment of choice for infantile hemangiomas." | 4.02 | Recurrence rate of infantile hemangioma after oral propranolol therapy. ( Byeon, JO; Frongia, G; Günther, P; Mehrabi, A, 2021) |
| "The outcomes of propranolol treatment remain controversial for parotid hemangiomas, which may be inferior to outcomes for infantile hemangiomas (IHs) at other sites." | 4.02 | Oral propranolol therapy in parotid hemangiomas: A retrospective comparison with other infantile hemangiomas. ( Bi, J; Gao, Q; Huo, R; Li, S; Li, X; Lv, R; Wang, L; Xu, G, 2021) |
| "Since the discovery of propranolol in the treatment of infantile hemangioma (IH), there has been emergent investigation of β-adrenergic receptor (β-AR) signaling in IH and the mechanisms of action for which β-AR blockers regulate hemangioma cell proliferation." | 3.96 | Rebound of Involuted Infantile Hemangioma After Administration of Salbutamol. ( Knöpfel, N; Oesch, V; Szello, P; Theiler, M; Weibel, L, 2020) |
| "To study the clinical effect of oral propranolol in the treatment of respiratory hemangioma in infants and young children." | 3.96 | [Clinical effect of propranolol in the treatment of respiratory hemangioma in infants and young children]. ( Chen, YQ; Ding, XF; Zhong, LL, 2020) |
| "Oral propranolol (OP) demonstrated high efficacy and safety profile for treatment of critical infantile hemangiomas (IHs)." | 3.96 | A new clinical and dermoscopic monitoring of infantile hemangiomas treated with oral propranolol. ( Caini, M; Cartocci, A; Cevenini, G; Cinotti, E; de Quattro, M; Fiorani, D; Ierardi, F; Oranges, T; Pianigiani, E; Rubegni, P; Tognetti, L, 2020) |
| "Few specific reports have addressed propranolol as a treatment for parotid hemangioma, and its mechanism remains unclear." | 3.83 | Use of propranolol for parotid hemangioma. ( Chang, L; Chen, H; Jin, Y; Lin, X; Lv, D; Ma, G; Qiu, Y; Wang, T; Yang, X; Ying, H; Yu, W, 2016) |
| "Propranolol has been widely used in treating infantile hemangiomas (IHs)." | 3.80 | Propranolol enhanced adipogenesis instead of induction of apoptosis of hemangiomas stem cells. ( Chang, M; Ma, X; Ma, Y; Ouyang, T; Xin, S; Zhao, T, 2014) |
| "Although propranolol has become the first-line therapy for infantile haemangiomas (IHs), no study has yet investigated factors associated with the risk of relapse in children with IH treated with propranolol after cessation of treatment." | 3.79 | Factors associated with the relapse of infantile haemangiomas in children treated with oral propranolol. ( Ahogo, CK; Boralevi, F; Colona, V; Diallo, A; Ezzedine, K; Léauté-Labrèze, C; Prey, S; Taïeb, A, 2013) |
| "To report the efficacy of propranolol as first-line treatment of head and neck hemangiomas in children and to present an optimized protocol for treating hemangiomas." | 3.77 | Propranolol as first-line treatment of head and neck hemangiomas. ( Ayari-Khalfallah, S; Froehlich, P; Fuchsmann, C; Giguere, C; Guibaud, L; McCone, C; Powell, J; Quintal, MC, 2011) |
| "The successful management of subglottic hemangioma with propranolol has been reported." | 3.76 | Management of infantile subglottic hemangioma: acebutolol or propranolol? ( Amedro, P; Bigorre, M; Blanchet, C; Mondain, M; Nicollas, R, 2010) |
| "Propranolol was useful as first-line or single-agent treatment of facial infantile haemangioma in Chinese children, and gave rise to minimal side-effects." | 3.76 | Use of propranolol in infantile haemangioma among Chinese children. ( Chan, HB; Chik, KK; Luk, CK; Tan, HY, 2010) |
| "Propranolol-treated patients also showed relative upregulation of CD34+ cell-associated gene transcripts (P = ." | 2.94 | Propranolol inhibits molecular risk markers in HCT recipients: a phase 2 randomized controlled biomarker trial. ( Chhabra, S; Cole, SW; D'Souza, A; Dhakal, B; Giles, KE; Hamadani, M; Hari, P; Horowitz, MM; Knight, JM; Logan, BR; Pasquini, MC; Rizzo, JD; Shah, N; Sriram, D, 2020) |
| "Infantile hemangiomas are the most common tumor of childhood and undergo rapid growth during early infancy followed by gradual involution." | 1.48 | Prolonged growth of infantile hemangioma after pulsed dye laser and oral propranolol treatment. ( Kagami, S; Kaneko, M; Katori, T; Kishi, A, 2018) |
| "Propranolol has been the first-line treatment for problematic infantile hemangioma (IH) since 2008." | 1.40 | Recurrence of infantile hemangioma after termination of propranolol treatment. ( Chang, L; Chen, H; Hu, X; Jin, Y; Lin, X; Ma, G; Qiu, Y; Yang, X; Ye, X; Yu, W, 2014) |
| "To evaluate the efficacy, adverse effects, and recurrence of oral propranolol for treatment of infantile hemangioma." | 1.39 | Propranolol therapy of infantile hemangiomas: efficacy, adverse effects, and recurrence. ( Li, Q; Xiao, Q; Yu, W; Zhang, B, 2013) |
| "Propranolol seems to be an effective modality of treatment for periocular IH." | 1.37 | Treatment of periocular infantile hemangiomas with propranolol: case series of 18 children. ( Al Dhaybi, R; Chevrette, L; Codère, F; Dubois, J; Fallaha, N; Hamel, P; Hatami, A; McCuaig, C; Milet, A; Ospina, LH; Powell, J; Superstein, R, 2011) |
| "Subglottic hemangioma is a rare, potentially life threatening tumor of infancy which poses serious treatment challenges." | 1.36 | Case report: Treatment failure using propanolol for treatment of focal subglottic hemangioma. ( Baum, ED; Canadas, KT; Lee, S; Ostrower, ST, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (3.70) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (3.70) | 29.6817 |
| 2010's | 15 (55.56) | 24.3611 |
| 2020's | 10 (37.04) | 2.80 |
| Authors | Studies |
|---|---|
| Tiwari, P | 1 |
| Bera, RN | 1 |
| Pandey, V | 1 |
| Zhanatkyzy, A | 1 |
| Gorbunov, D | 1 |
| Ivanova-Razumova, T | 1 |
| Baigalkanova, A | 1 |
| Manabay, A | 1 |
| Harris, J | 1 |
| Phillips, JD | 1 |
| Knight, JM | 1 |
| Rizzo, JD | 1 |
| Hari, P | 1 |
| Pasquini, MC | 1 |
| Giles, KE | 1 |
| D'Souza, A | 1 |
| Logan, BR | 1 |
| Hamadani, M | 1 |
| Chhabra, S | 1 |
| Dhakal, B | 1 |
| Shah, N | 1 |
| Sriram, D | 1 |
| Horowitz, MM | 1 |
| Cole, SW | 1 |
| Knöpfel, N | 1 |
| Oesch, V | 1 |
| Theiler, M | 1 |
| Szello, P | 1 |
| Weibel, L | 1 |
| Chen, YQ | 1 |
| Zhong, LL | 1 |
| Ding, XF | 1 |
| Tognetti, L | 1 |
| Pianigiani, E | 1 |
| Ierardi, F | 1 |
| Cartocci, A | 1 |
| Fiorani, D | 1 |
| de Quattro, M | 1 |
| Caini, M | 1 |
| Oranges, T | 1 |
| Cinotti, E | 1 |
| Cevenini, G | 1 |
| Rubegni, P | 1 |
| Heinhuis, KM | 1 |
| IJzerman, NS | 1 |
| Koenen, AM | 1 |
| van der Graaf, WTA | 1 |
| Haas, RL | 1 |
| Beijnen, JH | 1 |
| Huitema, ADR | 1 |
| van Houdt, WJ | 1 |
| Steeghs, N | 1 |
| Frongia, G | 1 |
| Byeon, JO | 1 |
| Mehrabi, A | 1 |
| Günther, P | 1 |
| Wang, L | 1 |
| Li, S | 1 |
| Gao, Q | 1 |
| Lv, R | 1 |
| Xu, G | 1 |
| Li, X | 1 |
| Bi, J | 1 |
| Huo, R | 1 |
| Kagami, S | 2 |
| Kaneko, M | 2 |
| Katori, T | 2 |
| Kishi, A | 1 |
| Kao, J | 1 |
| Luu, B | 1 |
| Xiao, Q | 1 |
| Li, Q | 1 |
| Zhang, B | 1 |
| Yu, W | 3 |
| Ahogo, CK | 1 |
| Ezzedine, K | 1 |
| Prey, S | 1 |
| Colona, V | 1 |
| Diallo, A | 1 |
| Boralevi, F | 1 |
| Taïeb, A | 1 |
| Léauté-Labrèze, C | 1 |
| Chang, L | 2 |
| Ma, G | 2 |
| Jin, Y | 2 |
| Ye, X | 1 |
| Qiu, Y | 2 |
| Chen, H | 2 |
| Yang, X | 2 |
| Hu, X | 1 |
| Lin, X | 2 |
| Ma, X | 1 |
| Zhao, T | 1 |
| Ouyang, T | 1 |
| Xin, S | 1 |
| Ma, Y | 1 |
| Chang, M | 1 |
| Lv, D | 1 |
| Ying, H | 1 |
| Wang, T | 1 |
| Choy, C | 1 |
| Raytis, JL | 1 |
| Smith, DD | 1 |
| Duenas, M | 1 |
| Neman, J | 1 |
| Jandial, R | 1 |
| Lew, MW | 1 |
| Phillips, RJ | 1 |
| Crock, CM | 1 |
| Penington, AJ | 1 |
| Bekhor, PS | 1 |
| Blanchet, C | 1 |
| Nicollas, R | 1 |
| Bigorre, M | 1 |
| Amedro, P | 1 |
| Mondain, M | 1 |
| Canadas, KT | 1 |
| Baum, ED | 1 |
| Lee, S | 1 |
| Ostrower, ST | 1 |
| Chik, KK | 1 |
| Luk, CK | 1 |
| Chan, HB | 1 |
| Tan, HY | 1 |
| Al Dhaybi, R | 1 |
| Superstein, R | 1 |
| Milet, A | 1 |
| Powell, J | 2 |
| Dubois, J | 1 |
| McCuaig, C | 1 |
| Codère, F | 1 |
| Hatami, A | 1 |
| Chevrette, L | 1 |
| Fallaha, N | 1 |
| Hamel, P | 1 |
| Ospina, LH | 1 |
| Fuchsmann, C | 1 |
| Quintal, MC | 1 |
| Giguere, C | 1 |
| Ayari-Khalfallah, S | 1 |
| Guibaud, L | 1 |
| McCone, C | 1 |
| Froehlich, P | 1 |
| Alamán Orbañanos, B | 1 |
| Negrete Calderón, N | 1 |
| Martín-Romo Capilla, J | 1 |
| Becerra Cayetano, A | 1 |
| Harrison, TS | 1 |
| Freier, DT | 1 |
| Cohen, EL | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Randomized Controlled Pilot Study Using Propranolol to Decrease Gene Expression of Stress-Mediated Beta-Adrenergic Pathways in Hematopoietic Stem Cell Transplant (HCT) Recipients[NCT02420223] | Phase 2 | 25 participants (Actual) | Interventional | 2015-07-17 | Completed | ||
| Phase 2 Study of Sildenafil for the Treatment of Lymphatic Malformations[NCT02335242] | Phase 2 | 22 participants (Actual) | Interventional | 2015-05-23 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Expression (up or down regulation) of genes involved in the stress response can be modulated through the beta-adrenergic pathway. The log2 RNA abundance is a means to normalize results to determine whether a gene is up regulated (value greater than 1) or down regulated (value less than 1). Differential change in log2 RNA abundance is defined by the fold change (FC) as log2FC=Log2(B)-Log2(A). Logarithmic measures are unitless. The change in the measure between two time points determines whether a gene has up-or down-regulated. (NCT02420223)
Timeframe: Baseline (Pre-Transplant); 4 weeks post-transplant
| Intervention | Unitless (Mean) |
|---|---|
| Propranolol | -0.407 |
| Control Arm | 0.0099 |
This measure is the number of subjects diagnosed with culture-positive infection or neutropenic fever greater than 100.4 degrees Fahrenheit. (NCT02420223)
Timeframe: Up to 100 days after transplant
| Intervention | Participants (Count of Participants) |
|---|---|
| Propranolol | 1 |
| Control Arm | 6 |
Number of subjects experiencing any of: fever, diarrhea or rash requiring steroid intervention within 48 hours before or after neutrophil recovery. (NCT02420223)
Timeframe: 4 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Propranolol | 6 |
| Control Arm | 3 |
This measure is the mean time to the beginning of three consecutive days where the neutrophil count (absolute neutrophil count) was 500 cells/mm^3 (0.5 x 10^9/L) or greater. (NCT02420223)
Timeframe: 4 weeks after transplant
| Intervention | Days (Mean) |
|---|---|
| Propranolol | 10.5 |
| Control Arm | 11.9 |
This measure is the mean time to the beginning of three consecutive days where the platelet count is at least 20,000/mm^3 (20 x 10^9/L) unsupported by a platelet transfusion. (NCT02420223)
Timeframe: 4 weeks
| Intervention | Days (Mean) |
|---|---|
| Propranolol | 16.6 |
| Control Arm | 19.6 |
This measure is the number of participants experiencing a response defined by the International Uniform Response Criteria as: very good partial response (VGPR) or better (near complete response (nCR), complete response (CR), and stringent CR (sCR) according to at day 100 post-Hematopoietic Cell Transplant. (NCT02420223)
Timeframe: 100 days after transplant
| Intervention | Participants (Count of Participants) | |||
|---|---|---|---|---|
| Stable Disease | Partial Response | Very Good Partial Response | Complete Response | |
| Control Arm | 0 | 5 | 5 | 3 |
| Propranolol | 1 | 5 | 5 | 1 |
This measure will be assessed using the Hospital Anxiety and Depression Scale (HADS). The HADS scale includes fourteen 4-response Likert-scale questions graded 0 to 3. Seven questions are specific to depression; 7 questions are specific to anxiety. The score is the total of the responses in their respective categories. Lower scores indicated less depression and/or anxiety. Scores 0-7 indicate normal status; scores 8-10 suggest borderline abnormal status; and scores 11-21 indicate abnormal status. Only anxiety scores are presented. (NCT02420223)
Timeframe: Baseline and 4 weeks
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline Anxiety Score | 4-Week Anxiety Score | |
| Control Arm | 7.4 | 5.2 |
| Propranolol | 7.3 | 4.4 |
Participants will be followed for the duration of the study, an expected average of 20 weeks. (NCT02335242)
Timeframe: Baseline, week 20
| Intervention | percentage of volume (Mean) |
|---|---|
| Double-Blind Placebo | 5.89 |
| Open-Label Sildenafil | -8.54 |
| Double-blind Sildenafil | -0.642 |
"Subject's evaluation of the overall change in lymphatic malformation. Participants will be followed from baseline to 20 weeks.~Patients rated change as no improvement, minimal improvement (1-25% change), fair improvement (25-50% change), good improvement (50-75% change), and excellent improvement (75-100% change)." (NCT02335242)
Timeframe: Baseline, week 20
| Intervention | Participants (Count of Participants) | ||||
|---|---|---|---|---|---|
| No improvement | Minimal improvement | Fair improvement | Good improvement | Excellent improvement | |
| Double-Blind Placebo | 1 | 2 | 0 | 2 | 0 |
| Double-Blind Sildenafil | 2 | 4 | 1 | 1 | 0 |
1 review available for propranolol and Local Neoplasm Recurrence
| Article | Year |
|---|---|
Can propranolol prevent progression of melanoma?
Topics: Adrenergic beta-Antagonists; Disease Progression; Humans; Melanoma; Neoplasm Recurrence, Local; Prop | 2019 |
3 trials available for propranolol and Local Neoplasm Recurrence
| Article | Year |
|---|---|
Propranolol inhibits molecular risk markers in HCT recipients: a phase 2 randomized controlled biomarker trial.
Topics: Biomarkers; Hematopoietic Stem Cell Transplantation; Humans; Leukocytes, Mononuclear; Neoplasm Recur | 2020 |
PropAngio study protocol: a neoadjuvant trial on the efficacy of propranolol monotherapy in cutaneous angiosarcoma-a proof of principle study.
Topics: Adrenergic beta-Antagonists; Hemangiosarcoma; Humans; Neoadjuvant Therapy; Neoplasm Recurrence, Loca | 2020 |
Thirty-two Japanese cases of infantile hemangiomas treated with oral propranolol.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Body Image; Female; Follow-Up Studies; Hemangioma | 2018 |
23 other studies available for propranolol and Local Neoplasm Recurrence
| Article | Year |
|---|---|
Bleomycin-triamcinolone sclerotherapy in the management of propranolol resistant infantile hemangioma of the maxillofacial region: A single arm prospective evaluation of clinical outcome and Doppler ultrasound parameters.
Topics: Bleomycin; Hemangioma; Humans; Neoplasm Recurrence, Local; Propranolol; Sclerotherapy; Treatment Out | 2023 |
Giant cardiac cavernous haemangioma of the right atrium in a newborn successfully managed using combined therapy.
Topics: Heart Atria; Heart Neoplasms; Hemangioma, Cavernous; Humans; Infant, Newborn; Neoplasm Recurrence, L | 2023 |
Evaluating the Clinical Outcomes of Parotid Hemangiomas in the Pediatric Patient Population.
Topics: Adrenal Cortex Hormones; Drug Administration Schedule; Female; Hemangioma; Hemangioma, Capillary; Hu | 2021 |
Rebound of Involuted Infantile Hemangioma After Administration of Salbutamol.
Topics: Adrenergic beta-2 Receptor Agonists; Albuterol; Bronchitis; Child, Preschool; Female; Hemangioma; Hu | 2020 |
[Clinical effect of propranolol in the treatment of respiratory hemangioma in infants and young children].
Topics: Administration, Oral; Adrenergic beta-Antagonists; Child; Child, Preschool; Hemangioma; Humans; Infa | 2020 |
A new clinical and dermoscopic monitoring of infantile hemangiomas treated with oral propranolol.
Topics: Hemangioma; Humans; Infant; Infant, Newborn; Neoplasm Recurrence, Local; Propranolol; Skin Neoplasms | 2020 |
Recurrence rate of infantile hemangioma after oral propranolol therapy.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Hemangioma; Humans; Infant; Neoplasm Recurrence, | 2021 |
Oral propranolol therapy in parotid hemangiomas: A retrospective comparison with other infantile hemangiomas.
Topics: Administration, Oral; Hemangioma; Humans; Infant; Neoplasm Recurrence, Local; Propranolol; Retrospec | 2021 |
Prolonged growth of infantile hemangioma after pulsed dye laser and oral propranolol treatment.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Female; Hemangioma; Humans; Infant; Lasers, Dye; | 2018 |
Propranolol therapy of infantile hemangiomas: efficacy, adverse effects, and recurrence.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Female; Follow-Up Studies; Hemangioma, Capillary; | 2013 |
Factors associated with the relapse of infantile haemangiomas in children treated with oral propranolol.
Topics: Administration, Oral; Antineoplastic Agents; Child; Child, Preschool; Female; Head and Neck Neoplasm | 2013 |
Recurrence of infantile hemangioma after termination of propranolol treatment.
Topics: Adrenergic beta-Antagonists; Female; Hemangioma, Capillary; Humans; Infant; Neoplasm Recurrence, Loc | 2014 |
Propranolol enhanced adipogenesis instead of induction of apoptosis of hemangiomas stem cells.
Topics: Adipogenesis; Antineoplastic Agents; Apoptosis; Blotting, Western; Cell Differentiation; Cells, Cult | 2014 |
Use of propranolol for parotid hemangioma.
Topics: Administration, Oral; Female; Hemangioma; Humans; Infant; Infant, Newborn; Male; Neoplasm Recurrence | 2016 |
Inhibition of β2-adrenergic receptor reduces triple-negative breast cancer brain metastases: The potential benefit of perioperative β-blockade.
Topics: Adrenergic beta-2 Receptor Antagonists; Adult; Aged; Aged, 80 and over; Animals; Brain Neoplasms; Ce | 2016 |
Prolonged tumour growth after treatment of infantile haemangioma with propranolol.
Topics: Child; Child, Preschool; Disease Progression; Female; Hemangioma; Humans; Infant; Infant, Newborn; M | 2017 |
Management of infantile subglottic hemangioma: acebutolol or propranolol?
Topics: Acebutolol; Adrenergic beta-Antagonists; Dose-Response Relationship, Drug; Drug Administration Sched | 2010 |
Case report: Treatment failure using propanolol for treatment of focal subglottic hemangioma.
Topics: Female; Follow-Up Studies; Glottis; Hemangioma; Humans; Infant; Laryngeal Neoplasms; Laryngoscopy; L | 2010 |
Use of propranolol in infantile haemangioma among Chinese children.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Child, Preschool; Dose-Response Relationship, Dru | 2010 |
Treatment of periocular infantile hemangiomas with propranolol: case series of 18 children.
Topics: Administration, Oral; Dose-Response Relationship, Drug; Eyelid Neoplasms; Female; Follow-Up Studies; | 2011 |
Propranolol as first-line treatment of head and neck hemangiomas.
Topics: Adrenal Cortex Hormones; Adrenergic beta-Antagonists; Child, Preschool; Female; Head and Neck Neopla | 2011 |
[Anesthetic management in a case of recurrent mediastinal paraganglioma].
Topics: 3-Iodobenzylguanidine; Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Anesthesia, Genera | 2008 |
Proceedings: Recurrent pheochromocytoma.
Topics: Abdominal Neoplasms; Adolescent; Adrenal Gland Neoplasms; Adult; Child; Epinephrine; Female; Hormone | 1974 |